BIOGEN INC (IDP.DE) Fundamental Analysis & Valuation
FRA:IDP • US09062X1037
Current stock price
160.9 EUR
-0.2 (-0.12%)
Last:
This IDP.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. IDP.DE Profitability Analysis
1.1 Basic Checks
- In the past year IDP was profitable.
- IDP had a positive operating cash flow in the past year.
- Each year in the past 5 years IDP has been profitable.
- Each year in the past 5 years IDP had a positive operating cash flow.
1.2 Ratios
- IDP has a Return On Assets of 4.39%. This is in the better half of the industry: IDP outperforms 75.90% of its industry peers.
- IDP's Return On Equity of 7.08% is fine compared to the rest of the industry. IDP outperforms 77.11% of its industry peers.
- The Return On Invested Capital of IDP (8.93%) is better than 78.31% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for IDP is below the industry average of 12.16%.
- The 3 year average ROIC (8.93%) for IDP is below the current ROIC(8.93%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.39% | ||
| ROE | 7.08% | ||
| ROIC | 8.93% |
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
1.3 Margins
- Looking at the Profit Margin, with a value of 13.07%, IDP is in the better half of the industry, outperforming 77.11% of the companies in the same industry.
- In the last couple of years the Profit Margin of IDP has declined.
- The Operating Margin of IDP (27.94%) is better than 81.93% of its industry peers.
- In the last couple of years the Operating Margin of IDP has declined.
- With a decent Gross Margin value of 75.69%, IDP is doing good in the industry, outperforming 63.86% of the companies in the same industry.
- In the last couple of years the Gross Margin of IDP has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.94% | ||
| PM (TTM) | 13.07% | ||
| GM | 75.69% |
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
2. IDP.DE Health Analysis
2.1 Basic Checks
- IDP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- IDP has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, IDP has less shares outstanding
- Compared to 1 year ago, IDP has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 3.32 indicates that IDP is not in any danger for bankruptcy at the moment.
- IDP's Altman-Z score of 3.32 is fine compared to the rest of the industry. IDP outperforms 65.06% of its industry peers.
- The Debt to FCF ratio of IDP is 3.11, which is a good value as it means it would take IDP, 3.11 years of fcf income to pay off all of its debts.
- IDP has a Debt to FCF ratio of 3.11. This is amongst the best in the industry. IDP outperforms 83.13% of its industry peers.
- A Debt/Equity ratio of 0.34 indicates that IDP is not too dependend on debt financing.
- The Debt to Equity ratio of IDP (0.34) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.34 | ||
| Debt/FCF | 3.11 | ||
| Altman-Z | 3.32 |
ROIC/WACC1.05
WACC8.47%
2.3 Liquidity
- IDP has a Current Ratio of 2.68. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
- IDP has a Current ratio of 2.68. This is comparable to the rest of the industry: IDP outperforms 55.42% of its industry peers.
- A Quick Ratio of 2.03 indicates that IDP has no problem at all paying its short term obligations.
- IDP has a Quick ratio (2.03) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.68 | ||
| Quick Ratio | 2.03 |
3. IDP.DE Growth Analysis
3.1 Past
- IDP shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.16%.
- Measured over the past years, IDP shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -14.17% on average per year.
- IDP shows a small growth in Revenue. In the last year, the Revenue has grown by 2.22%.
- IDP shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.96% yearly.
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%
3.2 Future
- The Earnings Per Share is expected to grow by 3.53% on average over the next years.
- Based on estimates for the next years, IDP will show a decrease in Revenue. The Revenue will decrease by -0.48% on average per year.
EPS Next Y5.16%
EPS Next 2Y4.3%
EPS Next 3Y4.87%
EPS Next 5Y3.53%
Revenue Next Year-3.98%
Revenue Next 2Y-2.43%
Revenue Next 3Y-1.25%
Revenue Next 5Y-0.48%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. IDP.DE Valuation Analysis
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 12.15 indicates a correct valuation of IDP.
- Based on the Price/Earnings ratio, IDP is valued cheaply inside the industry as 91.57% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Earnings ratio of 25.70, IDP is valued rather cheaply.
- The Price/Forward Earnings ratio is 11.56, which indicates a very decent valuation of IDP.
- Based on the Price/Forward Earnings ratio, IDP is valued cheaper than 97.59% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 23.84, IDP is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.15 | ||
| Fwd PE | 11.56 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, IDP is valued cheaply inside the industry as 90.36% of the companies are valued more expensively.
- 95.18% of the companies in the same industry are more expensive than IDP, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.5 | ||
| EV/EBITDA | 8.17 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- IDP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.36
PEG (5Y)N/A
EPS Next 2Y4.3%
EPS Next 3Y4.87%
5. IDP.DE Dividend Analysis
5.1 Amount
- No dividends for IDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
IDP.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:IDP (3/13/2026, 7:00:00 PM)
160.9
-0.2 (-0.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06 2026-02-06/bmo
Earnings (Next)04-29 2026-04-29
Inst Owners97.35%
Inst Owner ChangeN/A
Ins Owners0.16%
Ins Owner ChangeN/A
Market Cap23.61B
Revenue(TTM)9.89B
Net Income(TTM)1.29B
Analysts73.02
Price Target177.03 (10.02%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.18%
Min EPS beat(2)20.87%
Max EPS beat(2)21.48%
EPS beat(4)4
Avg EPS beat(4)24.64%
Min EPS beat(4)17.28%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)17.2%
EPS beat(12)12
Avg EPS beat(12)12.76%
EPS beat(16)15
Avg EPS beat(16)12.81%
Revenue beat(2)2
Avg Revenue beat(2)3.75%
Min Revenue beat(2)1.26%
Max Revenue beat(2)6.23%
Revenue beat(4)4
Avg Revenue beat(4)6.45%
Min Revenue beat(4)1.26%
Max Revenue beat(4)11.62%
Revenue beat(8)6
Avg Revenue beat(8)2.98%
Revenue beat(12)9
Avg Revenue beat(12)2.26%
Revenue beat(16)11
Avg Revenue beat(16)1.92%
PT rev (1m)6.89%
PT rev (3m)13.87%
EPS NQ rev (1m)-13.19%
EPS NQ rev (3m)-11.95%
EPS NY rev (1m)5.69%
EPS NY rev (3m)4.68%
Revenue NQ rev (1m)-1.38%
Revenue NQ rev (3m)-0.78%
Revenue NY rev (1m)1.15%
Revenue NY rev (3m)1.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.15 | ||
| Fwd PE | 11.56 | ||
| P/S | 2.76 | ||
| P/FCF | 13.5 | ||
| P/OCF | 12.37 | ||
| P/B | 1.49 | ||
| P/tB | 10.54 | ||
| EV/EBITDA | 8.17 |
EPS(TTM)13.24
EY8.23%
EPS(NY)13.92
Fwd EY8.65%
FCF(TTM)11.92
FCFY7.41%
OCF(TTM)13.01
OCFY8.09%
SpS58.36
BVpS107.73
TBVpS15.27
PEG (NY)2.36
PEG (5Y)N/A
Graham Number179.15
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.39% | ||
| ROE | 7.08% | ||
| ROCE | 10.59% | ||
| ROIC | 8.93% | ||
| ROICexc | 10.46% | ||
| ROICexgc | 35.29% | ||
| OM | 27.94% | ||
| PM (TTM) | 13.07% | ||
| GM | 75.69% | ||
| FCFM | 20.42% |
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
ROICexc(3y)9.96%
ROICexc(5y)13.03%
ROICexgc(3y)38.5%
ROICexgc(5y)36.85%
ROCE(3y)10.59%
ROCE(5y)12.95%
ROICexgc growth 3Y4.85%
ROICexgc growth 5Y-4.35%
ROICexc growth 3Y-13.95%
ROICexc growth 5Y-14.37%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
F-Score4
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.34 | ||
| Debt/FCF | 3.11 | ||
| Debt/EBITDA | 1.77 | ||
| Cap/Depr | 23.77% | ||
| Cap/Sales | 1.87% | ||
| Interest Coverage | 10.46 | ||
| Cash Conversion | 62.22% | ||
| Profit Quality | 156.18% | ||
| Current Ratio | 2.68 | ||
| Quick Ratio | 2.03 | ||
| Altman-Z | 3.32 |
F-Score4
WACC8.47%
ROIC/WACC1.05
Cap/Depr(3y)46.72%
Cap/Depr(5y)49.51%
Cap/Sales(3y)2.92%
Cap/Sales(5y)2.77%
Profit Quality(3y)138.91%
Profit Quality(5y)133.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
EPS Next Y5.16%
EPS Next 2Y4.3%
EPS Next 3Y4.87%
EPS Next 5Y3.53%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%
Revenue Next Year-3.98%
Revenue Next 2Y-2.43%
Revenue Next 3Y-1.25%
Revenue Next 5Y-0.48%
EBIT growth 1Y8.4%
EBIT growth 3Y-4.68%
EBIT growth 5Y-10.91%
EBIT Next Year16.69%
EBIT Next 3Y5.17%
EBIT Next 5Y1.28%
FCF growth 1Y-19.74%
FCF growth 3Y20.95%
FCF growth 5Y-11.3%
OCF growth 1Y-23.33%
OCF growth 3Y16.78%
OCF growth 5Y-12.22%
BIOGEN INC / IDP.DE Fundamental Analysis FAQ
What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE.
What is the valuation status for IDP stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
What is the profitability of IDP stock?
BIOGEN INC (IDP.DE) has a profitability rating of 6 / 10.
What is the financial health of BIOGEN INC (IDP.DE) stock?
The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.
What is the expected EPS growth for BIOGEN INC (IDP.DE) stock?
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to grow by 5.16% in the next year.